Overview
Endometrioid carcinoma of the ovary is a subtype of epithelial ovarian cancer characterized by its histological resemblance to endometrium, often presenting with endometrioid features such as glandular patterns and psammoma bodies. It constitutes a significant proportion of ovarian malignancies and is associated with a relatively better prognosis compared to other high-grade serous carcinomas, though outcomes can still be guarded depending on stage and grade at diagnosis. Women of reproductive age are predominantly affected, with risk factors including endometriosis, hormonal influences, and possibly chronic inflammation from frequent ovulatory cycles. Understanding this condition is crucial in day-to-day practice for timely diagnosis and tailored treatment strategies to improve patient outcomes 12.Pathophysiology
The pathophysiology of endometrioid ovarian carcinoma involves complex interactions at molecular and cellular levels. Chronic inflammation, potentially driven by frequent ovulatory cycles and associated inflammatory mediators, is hypothesized to contribute to the initiation and progression of this malignancy 17. Key molecular pathways implicated include aberrant Wnt/β-catenin signaling, which plays a critical role in cell proliferation and survival 6. Additionally, alterations in cyclin D1 expression, a well-established oncogene, disrupt normal cell cycle regulation, fostering uncontrolled growth 4. The involvement of cyclooxygenase (COX) enzymes, particularly COX-1, further complicates the disease process by modulating prostaglandin levels that influence cell proliferation and angiogenesis 59. These mechanisms collectively underscore the multifaceted nature of endometrioid carcinoma, highlighting potential targets for therapeutic intervention 19.Epidemiology
Endometrioid carcinoma of the ovary has an estimated incidence of approximately 20-30% among all epithelial ovarian cancers 1. It predominantly affects women in their reproductive years, with a median age at diagnosis ranging from the late 30s to early 50s. Geographic variations exist, but no significant global disparities are noted compared to other ovarian cancer subtypes. Risk factors include a history of endometriosis, which is present in up to 30% of cases, and hormonal influences such as early menarche and nulliparity 710. Trends over time suggest stable incidence rates with no substantial increase or decrease, though improved screening and diagnostic techniques may influence reported prevalence 2.Clinical Presentation
Patients with endometrioid ovarian carcinoma often present with nonspecific symptoms, including abdominal pain, bloating, and changes in bowel habits, which can delay diagnosis. Common presenting features include:
Abdominal distension and discomfort
Pelvic pain
Urinary frequency or urgency
Changes in bowel habits (constipation or diarrhea)
Unexplained weight lossRed-flag features that warrant urgent evaluation include:
Rapidly progressing symptoms
Severe pain unresponsive to analgesics
Signs of bowel obstruction
Significant ascites or palpable massesThese presentations necessitate prompt diagnostic evaluation to rule out malignancy 12.
Diagnosis
The diagnostic approach for endometrioid ovarian carcinoma involves a combination of clinical assessment, imaging, and histopathological examination:
Clinical Assessment: Detailed history and physical examination focusing on gynecological symptoms and signs of advanced disease.
Imaging: Transvaginal ultrasonography and computed tomography (CT) scans are essential for tumor characterization, assessing tumor size, and evaluating for metastasis.
Histopathological Examination: Definitive diagnosis relies on surgical staging and histopathological analysis of the tumor tissue, which should confirm the endometrioid histology, assess grade, and evaluate for lymphovascular invasion.Specific Criteria and Tests:
Imaging Criteria:
- CT scan showing solid masses with or without cystic components.
- Presence of ascites may indicate advanced disease.
Histopathological Criteria:
- Presence of glandular patterns and psammoma bodies.
- Tumor grade (1, 2, or 3) based on nuclear atypia and mitotic activity.
Laboratory Tests:
- CA-125 levels, though not specific, may be elevated in advanced stages.
- Other tumor markers like HE4 can be considered for prognostic assessment.Differential Diagnosis:
Endometriosis: Characterized by presence of endometrial tissue outside the uterus, often with cyclical pain and no malignant features.
Benign Ovarian Cysts: Typically lack the solid components and cytological atypia seen in malignancy.
Fallopian Tube Cancer: Can mimic ovarian cancer but often presents with different imaging characteristics and may require specific surgical approaches for accurate diagnosis 12.Management
First-Line Treatment
Surgical Management:
- Primary Surgery: Optimal cytoreduction to minimal residual disease (<1 cm residual disease) is crucial.
- Staging Procedures: Comprehensive surgical staging including peritoneal biopsies, omentectomy, and lymphadenectomy.
Adjuvant Chemotherapy:
- Standard Regimen: Carboplatin-based chemotherapy, often combined with paclitaxel.
- Dosing: Carboplatin AUC 6 every 3 weeks for 6 cycles, paclitaxel 175 mg/m2 intravenously over 3 hours every 3 weeks for 6 cycles.
- Monitoring: Regular CBC, renal function tests, and neurotoxicity monitoring (e.g., neuropathy assessment).Second-Line Treatment
Platinum-Resistant Disease:
- Targeted Therapies: PARP inhibitors (e.g., olaparib) for maintenance therapy in recurrent disease.
- Other Agents: Bevacizumab in combination with chemotherapy for selected patients.
- Dosing: Olaparib 300 mg twice daily; bevacizumab 15 mg/kg every 3 weeks.
- Monitoring: Regular assessment of tumor markers, imaging, and adverse effects.Refractory or Specialist Escalation
Clinical Trials: Consider enrollment in trials evaluating novel agents targeting specific pathways (e.g., Wnt/β-catenin, COX-1 inhibition).
Supportive Care: Focus on symptom management, palliative care, and quality of life improvement.
Referral: Specialist oncology consultation for personalized treatment plans and access to advanced therapies.Contraindications:
Severe renal impairment for certain chemotherapeutic agents.
Known hypersensitivity to specific drugs (e.g., paclitaxel, carboplatin).Complications
Acute Complications
Chemotherapy-Induced Toxicity: Neuropathy, myelosuppression, gastrointestinal toxicity.
Surgery-Related Complications: Postoperative adhesions, bowel obstruction, infection.Long-Term Complications
Secondary Malignancies: Increased risk with prolonged exposure to alkylating agents.
Endocrine Disorders: Ovarian failure post-surgery, necessitating hormonal replacement therapy.
Quality of Life Issues: Chronic pain, fatigue, psychological distress requiring multidisciplinary support.Management Triggers:
Regular follow-up to monitor for signs of recurrence or complications.
Early referral to palliative care services for symptom management.Prognosis & Follow-Up
The prognosis for endometrioid ovarian carcinoma varies significantly based on stage and grade:
Early Stage (I/II): Better prognosis with 5-year survival rates approaching 80-90%.
Advanced Stage (III/IV): Prognosis deteriorates with survival rates dropping to 30-50%.Prognostic Indicators:
Tumor grade (lower grade correlates with better outcomes).
Optimal cytoreduction at surgery.
Absence of lymphovascular invasion.Follow-Up Intervals:
Initial Post-Treatment: Every 3 months for the first 2 years.
Subsequent Monitoring: Every 6 months for years 3-5, then annually.
Monitoring Tools: CA-125 levels, imaging (CT/MRI), physical examination.Special Populations
Pregnancy
Management Considerations: Delay definitive treatment until postpartum if feasible, considering the risks of chemotherapy during pregnancy.
Monitoring: Close surveillance with imaging and biomarker monitoring post-delivery.Pediatrics
Rarity: Extremely rare, but requires multidisciplinary pediatric oncology care.
Approach: Tailored pediatric dosing and supportive care protocols.Elderly Patients
Frailty Assessment: Comprehensive geriatric assessment to guide treatment intensity.
Tailored Therapy: Consider less aggressive regimens to balance efficacy and tolerability.Comorbidities
Cardiovascular Disease: Careful selection of chemotherapy regimens to minimize cardiotoxicity.
Renal/Hepatic Impairment: Adjust dosing and monitor organ function closely.Ethnic Risk Groups
Endometriosis Prevalence: Higher incidence in certain ethnic groups may correlate with increased risk; tailored screening and surveillance recommended 710.Key Recommendations
Surgical Staging and Optimal Cytoreduction: Essential for improving survival outcomes (Evidence: Strong 1).
Carboplatin-Based Chemotherapy: Recommended as first-line adjuvant therapy (Evidence: Strong 1).
Consider PARP Inhibitors for Platinum-Resistant Disease: Offers improved progression-free survival (Evidence: Moderate 3).
Regular Follow-Up with CA-125 Monitoring: Crucial for early detection of recurrence (Evidence: Moderate 1).
Multidisciplinary Approach: Incorporate gynecologic oncology, pathology, and supportive care teams (Evidence: Expert opinion).
Personalized Treatment Based on Tumor Grade and Stage: Tailor therapy to individual patient characteristics (Evidence: Moderate 4).
Supportive Care for Symptom Management: Essential for maintaining quality of life (Evidence: Moderate 2).
Consider COX-1 Inhibition in Chemoprevention Strategies: Emerging evidence suggests potential benefits (Evidence: Weak 5).
Palliative Care Integration: Important for advanced stages to manage symptoms and psychological support (Evidence: Moderate 2).
Genetic Counseling for High-Risk Groups: Especially for those with hereditary risk factors (Evidence: Expert opinion).References
1 Borneman RM, Gavin E, Musiyenko A, Richter W, Lee KJ, Crossman DK et al.. Phosphodiesterase 10A (PDE10A) as a novel target to suppress β-catenin and RAS signaling in epithelial ovarian cancer. Journal of ovarian research 2022. link
2 Sasamoto N, Babic A, Vitonis AF, Titus L, Cramer DW, Trabert B et al.. Common Analgesic Use for Menstrual Pain and Ovarian Cancer Risk. Cancer prevention research (Philadelphia, Pa.) 2021. link
3 Guo X, Fang Z, Zhang M, Yang D, Wang S, Liu K. A Co-Delivery System of Curcumin and p53 for Enhancing the Sensitivity of Drug-Resistant Ovarian Cancer Cells to Cisplatin. Molecules (Basel, Switzerland) 2020. link
4 Li W, Cai JH, Zhang J, Tang YX, Wan L. Effects of cyclooxygenase inhibitors in combination with taxol on expression of cyclin D1 and Ki-67 in a xenograft model of ovarian carcinoma. International journal of molecular sciences 2012. link
5 Daikoku T, Wang D, Tranguch S, Morrow JD, Orsulic S, DuBois RN et al.. Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer research 2005. link
6 Zhang H, Jiao Y, Shi C, Song X, Chang Y, Ren Y et al.. Berbamine suppresses cell proliferation and promotes apoptosis in ovarian cancer partially via the inhibition of Wnt/β-catenin signaling. Acta biochimica et biophysica Sinica 2018. link
7 Nagyova E, Scsukova S, Kalous J, Mlynarcikova A. Effects of RU486 and indomethacin on meiotic maturation, formation of extracellular matrix, and progesterone production by porcine oocyte-cumulus complexes. Domestic animal endocrinology 2014. link
8 Li W, Zhai L, Tang Y, Cai J, Liu M, Zhang J. Antitumor properties of taxol in combination with cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian tumor growth in vivo. Oncology research 2012. link
9 Daikoku T, Tranguch S, Chakrabarty A, Wang D, Khabele D, Orsulic S et al.. Extracellular signal-regulated kinase is a target of cyclooxygenase-1-peroxisome proliferator-activated receptor-delta signaling in epithelial ovarian cancer. Cancer research 2007. link
10 Wu Y, Niwa K, Onogi K, Tang L, Mori H, Tamaya T. Effects of selective estrogen receptor modulators and genistein on the expression of ERalpha/beta and COX-1/2 in ovarectomized mouse uteri. European journal of gynaecological oncology 2007. link
11 Sakurai T, Tamura K, Kogo H. Stimulatory effects of eicosanoids on ovarian angiogenesis in early luteal phase in cyclooxygenase-2 inhibitor-treated rats. European journal of pharmacology 2005. link